Ophthalmic companies report updates on recent regulatory moves, studies and trials.
The FDA approved Lytenava (bevacizumab-vikg, Outlook Therapeutics) for the treatment of neovascular age-related macular degeneration.
The FDA granted 510(k) clearance for iPredict-DR (iHealthScreen), an AI-powered screening software designed to detect more than mild diabetic retinopathy in adults with diabetes.
The FDA cleared an expanded indication for the TearCare system (Sight Sciences). The system can be used to improve meibomian gland function in evaporative dry eye disease.
The FDA granted 510(k) clearance